RPG Life Sciences Q3 FY26 Investor Presentation Released
RPG Life Sciences released its Q3 FY26 investor presentation. For Q3 FY26, revenue was ₹180.0 crore. For 9M FY26, revenue reached ₹530.6 crore. Domestic Formulations contributed 71% to sales. The company is focused on building mega brands, expanding API business, and pursuing M&A, with ₹140 crore capex invested since FY22.
The release of quarterly financial results and an investor presentation is a standard disclosure for publicly listed companies. It provides investors with essential information for decision-making, thus having a medium impact on the market's perception and valuation.
The announcement is a routine release of an investor presentation detailing financial results and business strategy. While it provides factual information about performance and future plans, it does not contain significant positive or negative news that would strongly influence sentiment.
RPG Life Sciences Limited has released its investor presentation for the quarter ended December 31, 2025. The presentation provides a detailed overview of the company's performance, business segments, and strategic initiatives.
The company reported financial results for Q3 FY26 and 9M FY26. For Q3 FY26, Revenue from Operations stood at ₹180.0 crore, with EBITDA at ₹43.2 crore and PBT at ₹37.5 crore. PAT was ₹27.9 crore. For 9M FY26, Revenue from Operations was ₹530.6 crore, EBITDA was ₹127.4 crore, PBT was ₹111.2 crore, and PAT was ₹82.6 crore.
Key business segments for 9M FY26 include Domestic Formulations (DF) contributing 71% to sales, International Formulations (IF) at 18%, and API at 11%. DF sales grew by 8.9% to ₹364.6 crore, IF sales grew by 6.1% to ₹100.2 crore, while API sales decreased by 19.4% to ₹61.7 crore, impacted by a fire incident.
The company highlighted its business strategy, focusing on building mega brands (like Naprosyn and Immunosuppressants), expanding its API business, strengthening digital initiatives, pursuing mergers and acquisitions, developing new products, investing in talent, and enhancing manufacturing capabilities with ₹140 crore capex infused since FY22. RPG Life Sciences continues to be debt-free, with long-term and short-term credit ratings reaffirmed by ICRA.
What to do with a filing like this
RPG Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by RPG Life Sciences Limited. Read the original for the full detail.